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Regulatory T cells (Tregs) are crucial in maintaining tolerance. Hence, Treg
immunotherapy is an attractive therapeutic option in autoimmune diseases and organ
transplantations. Currently, autoimmune diseases do not have a curative treatment
and transplant recipients require life-long immunosuppression to prevent graft rejection.
There has been significant progress in understanding polyclonal and antigen-specific
Treg biology over the last decade. Clinical trials with good manufacturing practice
(GMP) Treg cells have demonstrated safety and early efficacy of Treg therapy. GMP
Treg cells can also be tracked following infusion. In order to improve efficacy of Tregs
immunotherapy, it is necessary that Tregs migrate, survive and function at the specific
target tissue. Application of antigen specific Tregs and maintaining cells’ suppressive
function and survival with low dose interleukin-2 (IL-2) will enhance the efficacy and
longevity of infused GMP-grade Tregs. Notably, stability of Tregs in the local tissue can
be manipulated by understanding the microenvironment. With the recent advances in
GMP-grade Tregs isolation and antigen-specific chimeric antigen receptor (CAR)-Tregs
development will allow functionally superior cells to migrate to the target organ. Thus,
Tregs immunotherapy may be a promising option for patients with autoimmune diseases
and organ transplantations in near future.
Keywords: regulatory T cell, liver transplant, autoimmune liver diseases, antigen specific, recruitment, tolerance,
polyclonal
BACKGROUND OF REGULATORY T CELLS
Naturally occurring CD4+CD25high regulatory T (Treg) cells maintain peripheral self-tolerance in
rodents and humans (1, 2). In 1995, Sakaguchi and colleagues demonstrated that adoptive transfer
of a subset of CD4+ T cells expressing the IL-2 receptor α-chain (CD25) prevented autoimmunity
(1). CD4+CD25high T cells constitute 5 to 10% of CD4+ T cells in the blood (3) and they are
able to maintain immunologic self-tolerance and transplantation tolerance by actively suppressing
self-reactive, alloantigen-reactive lymphocytes. Treg cells prevent activation and expansion of
auto-reactive T cells that escape clonal deletion in the thymus.
Treg cell development and function is controlled by the transcription factor Foxp3, however
defects can lead to autoimmune and inflammatory syndromes in humans and mice (4).
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Immunodysregulation, polyendocrinopathy, X-linked (IPEX)
syndrome, a rare X-linked recessive disorder, was first described
in 1982 in which mutations in the Foxp3 gene caused defective
development of CD4+CD25high Treg cells (5). Similarly,
lymphoproliferation and multi-organ autoimmunity in
scurfy mutant mice was caused by mutations in Foxp3 (6).
Further to this, expression of the IL-7 receptor, CD127,
correlated inversely with Foxp3 expression and Treg cell
suppressive function; hence Treg cells are currently defined as
CD4+CD25highCD127lowFoxp3+ cells (7, 8).
Treg cells main function is to control auto-reactive T cells via
multiple mechanisms. Treg cells express CTLA-4 and suppress
effector T cells, via endocytosis of CD80/CD86 molecules
expressed on antigen presenting dendritic cells (9). They can also
secrete immunosuppressive cytokines (interleukin-10), cytotoxic
granzymes and immunomodulatory molecule, kynurenine. Treg
cells can generate the immunosuppressive molecule, adenosine,
via CD39 expressed on the cell surface (8). By continuously
surveying and controlling self-reactive T effector cells, Treg
cells are crucial in restoring tolerance in both autoimmunity
and transplantation.
TYPES OF REGULATORY T CELLS
CD4+CD25high Foxp3+ Treg cells are a heterogeneous
population, often categorized into two main subtypes, which
include thymic-derived natural Treg (tTreg) cells and peripheral-
derived Treg (pTreg) cells (10, 11). Both subtypes act in a
complementary manner to maintain peripheral tolerance. tTreg
cells express Foxp3, however Foxp3 is transiently induced in
pTreg cells; they may not have high levels of Treg specific
demethylated region (TSDR), a conserved region within the
Foxp3 gene (12). pTreg cells recognize non-self-antigens, such
as those encountered in the gut and airways, in addition to
providing maternal-fotal tolerance and commensal micro-biota
tolerance (13–15). pTreg cells develop from conventional T
cells once they have been exposed to non-self-antigens and
transforming growth factor-β (16, 17). Although tTreg cells and
pTreg cells can be distinguished by using epigenetics markers,
phenotypically they share the same surface markers, which
poses difficulty in specifically isolating tTreg cells for subsequent
therapeutic purposes.
INTERLEUKIN-2
Treg cell survival and function is dependent on the cytokine,
interleukin-2 (IL-2) (18), which is required for maintaining
effective levels of functional Treg cells in autoimmune disease
(AID) (19–21). The cell surface receptor for IL-2 (IL-2R) is
composed of three subunits, alpha (IL-2RA, CD25), beta (IL-2RB,
CD122), and gamma (IL-2RG, CD132). Treg cells constitutively
express IL-2RA. IL-2RA is required for high-affinity IL-2 binding,
whilst IL-2RB and IL-2RG transduce the IL-2 signal (22).
Owing to their high levels of high-affinity CD25, Treg cells
competitively consume IL-2, thereby maintaining their survival
and function, whilst suppressing bystander effector cells (23, 24).
Where IL-2 availability is low, such as in the inflamed hepatic
microenvironment, Treg cell function may be compromised and
be inadequate to counteract the activated immune infiltrate (25).
At tissue level, Treg cell suppression is via IL-2 and CTLA-4
dependent mechanisms, yet tissue Treg cells, such as intrahepatic
Treg cells, constitutively express CTLA-4 (25, 26). CTLA-4 can
capture its ligands, CD80 and CD86, from antigen presenting
cells (APCs) by trans-endocytosis, there by acting as an effector
molecule to inhibit CD28 co-stimulation by the cell-extrinsic
depletion of ligands (9).
AUTOIMMUNE DISEASES
The pathogenesis of AID is attributed by genetic susceptibilities,
environmental factors, and gut micro-biota (27). The majority of
organs and tissues in humans are susceptible to AIDs; such as
in solid organs (liver–autoimmune liver diseases and kidneys–
autoimmune glomerulonephritis), brain (multiple sclerosis),
lung (autoimmune idiopathic lung fibrosis), gut (Coeliac
disease, pernicious anemia, inflammatory bowel diseases),
skin (psoriasis, pemphigus, erythema nodosum), endocrine
(autoimmune thyroiditis, diabetes, Addison’s disease), andmulti-
organ involvement, for example, systemic lupus erythematosus
(SLE) (Figure 1).
Autoimmune liver diseases (AILDs) include autoimmune
hepatitis (AIH), primary biliary cholangitis (PBC) and primary
sclerosing cholangitis (PSC) (28, 29). Both AIDs and AILDs
are immune mediated diseases of unknown etiology, and occur
as a result of a breakdown in immune homeostasis (30).
Immunological homeostasis in humans is maintained between a
balance of effector T cells and Treg cells. It is now accepted that
there is a lack of control of self-reactive T effectors cells by Treg
cells in AIDs (31). Most AIDs co-exist with other autoimmune
conditions in the same individual (Figure 1), therefore, restoring
the tolerance in one autoimmune condition may also alleviate
other AIDs, if the origin of initial pathology stems from the
same tissue.
Therapies targeting AIDs, often aim to inhibit pro-
inflammatory immune responses by preventing activation
of immune cells in the target organ or diminishing tissue specific
T cell populations (32). Treg cells play a role in restoring multiple
human liver autoimmune conditions, however, Treg-directed
therapies could potentially inhibit protective immune responses
and lead to a higher risk of susceptibility to infection (31). As
Treg cells have significant immune-homeostatic properties to
prevent autoimmunity in mice and human, Treg-based cellular
therapies have gained extensive interest in the past decade.
Yet, most approaches to suppress autoimmunity currently use
polyclonal Treg cells due to their success in animal models.
Polyclonal Treg cells have several limitations, such as
the possibility of inducing global immunosuppression and
predisposing patients to infection. These limitations may be
overcome by using auto-antigen specific Treg cells. Most
investigators are currently focusing on the suppression of auto-
reactive T cells in an antigen-specific manner (33, 34). The
use of T cell receptor (TCR) transgenic mice confirmed that
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FIGURE 1 | Autoimmune diseases in multiple organs in humans. e.g. autoimmune diseases that can co-exist in multiple tissues are: brain (multiple sclerosis), eye
(autoimmune iritis and episcleritis), lung (autoimmune idiopathic pulmonary fibrosis), gut (Coeliac disease, pernicious anemia, inflammatory bowel disease),
liver—autoimmune liver diseases (autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis), kidneys (autoimmune glomerulonephritis), skin
(psoriasis, pemphigus), endocrine (autoimmune thyroid disease such as Hashimoto thyroiditis, Graves’ disease, type 1 diabetes, Addison’s disease), and multi-organ
involvement, such as systemic lupus erythematosus.
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antigen-specific Treg cells are more potent and efficacious
in autoimmune diabetes (35). Although antigen-specific Treg
cells provide a new direction for Treg cellular therapy, the
challenges remain in isolating and expanding antigen-specific
Treg cells, in addition to a lack of understanding of their
mechanism of suppression, survival and plasticity. These aspects
require addressing before embarking on organ-specific Treg
cellular therapy.
POLYCLONAL REGULATORY T CELLS
AND LOW DOSE IL-2 THERAPY IN
AUTOIMMUNE DISEASE
In healthy individuals, antigens can be efficiently eliminated
without damaging their own tissue, due to the removal or
inactivation of self-reactive cells, without posing a threat
to the individual (36). Yet, when there is a breakdown in
peripheral tolerance, the control of self-reactive cells can become
dysregulated and aberrant immune responses can lead to harmful
effects in their own tissue, which may lead to the development of
AID (8). Reduction in the frequency of Treg cells or a decline
in their function has been reported in various autoimmune
condition settings (37). Failure of Treg cells to suppress effector
cells is a typical feature of autoimmunity and has led to studies
exploring the use of either polyclonal (38, 39) or antigen-specific
Treg cells (40–42) as cellular therapies for AIDs (43).
AIDs can affect specific organs of the body (Figure 1).
Multiple sclerosis is a debilitating and known AID of the nervous
system. As mentioned, AILD includes AIH, PBC, and PSC.
Autoimmune endocrine diseases include autoimmune thyroiditis
(both Hashimoto and Grave’s disease) Sjogren’s syndrome, and
type-1 diabetes mellitus. Autoimmune musculo-skeletal diseases
are ankylosing spondylitis, rheumatoid arthritis, pemphigus
and psoriasis. Further to this, gastrointestinal autoimmune
conditions comprise of coeliac disease, pernicious anemia, and
inflammatory bowel diseases (Figure 1). AIDs can also affect
multiple organs and tissues in the same patient, for example,
autoimmune PBC patients often have associated Sjogren’s
syndrome and autoimmune thyroid disease (28).
Adoptive Treg cell therapy has been applied in SLE patients
with active skin disease (44). The study demonstrated that
Treg cell accumulation in the skin was associated with a
marked attenuation of the interferon-γ pathway and a reciprocal
augmentation of the interleukin-17 pathway (44). Additionally,
goodmanufacturing practice (GMP) Treg cell therapy in children
with another autoimmune condition, Type 1 diabetes mellitus,
demonstrated that Treg therapy was safe without any serious
side effects, at a Treg cell dose ranging from 10–20 millions/Kg.
Children were followed up for a year and the trial revealed
that there was a lower insulin requirement and higher C
peptides compared to the control patient group (39, 45). A
recent trial from UCSF on adult patients with diabetes that
utilized GMP polyclonal Treg cells ranging from 5 million
to 2.6 billion showed that Treg cell therapy is safe and that
there was stable C peptide levels and insulin for 2 years after
GMP Treg cell therapy. Cells were labeled with Deuterium and
could be traced in the circulation for up to 12 months (38).
In addition, CD4+CD25+CD127lowCD45RA+ Treg cells have
been suggested as the most suitable subset for GMP Treg cell
trial in inflammatory bowel disease (46). Thus, there are many
investigators attempting to restore tolerance in AIDs with direct
application of Treg cells to patients.
In addition to GMP-Treg cell infusion, Treg cell enhancing
therapy with very low dose IL-2, has also been applied in
various AIDs. In HCV induced vasculitis (47), this therapy
has been shown to be safe and led to Treg cell recovery
with concomitant clinical improvements in patients who had
cutaneous vasculitis. Additionally, a randomized double blind
clinical trial using subcutaneous low dose IL-2 on alternate
days for 2 weeks, followed by a 2-week break at a dose of 1
million IU or placebo, in patients with active SLE, suggested that
low dose IL-2 was again safe and may be an effective therapy
(48). Immunological and clinical efficacy of low dose IL-2 was
assessed in a recent open-label, phase I-IIa study of 46 patients
with multiple autoimmune conditions: including rheumatoid
arthritis, ankylosing spondylitis, SLE, psoriasis, Behcet’s disease,
granulomatosis with polyangiitis, Takayasu’s disease, Crohn’s
disease, ulcerative colitis, AIH or PSC. All patients received low
dose IL-2 (1 million IU/day) for 5 days, followed by fortnightly
injections for 6 months. The results suggested that low dose IL-2
was well tolerated in all AIDs, in addition to observing Treg cell
expansion and activation in all patients, without effector T cell
activation (49, 50).
POLYCLONAL REGULATORY T CELLS
AND LOW DOSE IL-2 THERAPY IN
AUTOIMMUNE LIVER DISEASE
As previously mentioned, AILDs include AIH, which affects
hepatocytes, PBC and PSC, which affects bile ducts. Functional
impairment or quantitative deficiency of Treg cells has
been described in AILD (25, 51, 52). In AIH, hepatocytes,
which constitute around 70% of liver cells, are mainly
damaged by auto-reactive T cells (51, 53–55). PBC affects the
intrahepatic bile ducts and PSC affects both the intra- and
extrahepatic bile ducts and is associated with inflammatory bowel
disease. Current therapies for AILD are non-curative, provide
unsatisfactory control of hepatic and biliary inflammation and
require long-term immunosuppressive medications that carry
unfavorable side effects. Thus, autologous Treg cell therapy
is an attractive option for the treatment of AILD, which
could provide long-term immune-regulation without requiring
global immunosuppression.
To work effectively, adoptively transferred Treg cells must
migrate to and mediate suppression of auto-reactive T cells at the
targeted tissue. Chemokines direct the trafficking and positioning
of leukocytes within the tissue by attracting T cells, which express
the corresponding chemokine receptors (56, 57). Deficiency of
chemokine receptor, CXCR3, which drives recruitment of T
cells across hepatic sinusoids (25, 58) has been associated with
the exacerbation of liver disease and abrogation of tolerance
in mouse models of immune-mediated hepatitis (59). A recent
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report by Oo and colleagues described that around 22–44% of
infused GMP Treg cells migrate to the human autoimmune liver
via utilizing CXCR3 (60). There is also another registered Phase 1
clinical trial to treat AIH patients with Treg cells (NCT02704338)
yet the result is still awaited.
The stability of Treg cells at the site of hepatic inflammation
is crucial. Our group has previously demonstrated that Treg
cells expressing Treg Th1 phenotype are more common in an
inflamed liver microenvironment (25). In addition, our recent
data suggested that the human liver has low levels of IL-2 that
may not support Treg cell survival (26). Based on this data, low
dose IL-2 was administered in two patients with refractory AIH
and an increase in the frequency of Treg cells in the peripheral
circulation was observed (61).
ORGAN TRANSPLANTATIONS
Transplantation provides the best chance of survival in organ
failure or cancer and has become a routine clinical treatment
option for many patients. Bone marrow, heart, liver, and kidney
transplantations are performed in many countries however,
recently the transplantation field has progressed to islet cell and
multi-visceral transplantations in some centers (Figures 2, 3).
Due to the current demand of organ donors exceeding the
number of transplantable organs, live donation (liver and
kidneys), and split graft transplants (liver) have become a vital
option (62).
In the early period following transplantation, both direct and
indirect pathways of antigen presentation by donor and recipient
dendritic cells play a role in graft rejection (63). Transplant
recipients are required to take long-term immunosuppression
to prevent graft loss. Graft rejection is driven by an imbalance
in the adaptive T and B immune cells: mainly a decline in the
frequency of Treg cells or impairment in Treg cell function,
which controls alloantigen specific T cells. To prevent graft
rejection in both live and cadaveric transplantation, switching
the immune balance toward the regulatory arm with Treg
cellular therapy has become an exciting therapeutic option. Two
main aims of Treg immunotherapy are 1) to restore immune
tolerance and 2) to avoid life-long immunosuppression following
transplantation. The side effects of immunosuppression range
from sepsis, hypertension, diabetes, and renal dysfunction,
to, the long term-effects of malignancies and post-transplant
lymphoproliferative disorder (PTLD).
In the context of living-related liver and kidney
transplantation, Treg cell infusion could be planned in advance.
For example, recipient Treg cells could be isolated several weeks
prior to the organ transplant and expanded with donor-derived
APCs (dendritic cells, monocytes or B cells). This would allow
sufficient numbers to be obtained in order to infuse them back
into the organ recipient within the first few days post-transplant
when immunosuppression and microenvironment milieu is
optimized (Figures 2 and 3). Recipient Treg generation could
be 1) polyclonal (if recipient Treg cells are expended with CD3,
CD28 beads, IL-2 and Rapamycin) or 2) antigen-specific (if
recipient Treg cells are expanded with donor APCs primed with
the donor antigen) (Figure 2). Thus, autologous, polyclonal
or antigen-specific Treg cell therapy can be administered to
the liver or kidney organ transplant recipient immediately
following transplantation. This could potentially lead to
prevention of early graft rejection with a potential withdrawal of
life-long immunosuppression.
Multiple clinical trials are registered for polyclonal Treg
cell immunotherapy or low dose IL-2 cytokine therapy,
in autoimmune conditions and organ transplantations
(clinicalTrials.gov) (Table 1). These trials are currently
being carried out or completed with CD4+CD25high or
CD4+CD25highCD127low populations, which are GMP cell-
sorted and expanded with TCR stimulation, or subcutaneous
administration of low dose IL-2 (Aldesleukin). So far, there
is no clinical trial completed with antigen-specific Treg
cell immunotherapy.
POLYCLONAL REGULATORY T CELLS
AND LOW DOSE IL-2 THERAPY IN HUMAN
TRANSPLANTATIONS
Polyclonal Treg cells have been applied in bone marrow
and solid organ transplantations with a view to either
reduce immunosuppression or achieve transplant tolerance
without requiring immunosuppression. Treg cells mediate
suppression of anti-donor immune responses, thus Treg
cell enrichment following bone marrow, liver, and kidney
transplantation could potentially lead to immunosuppression-
free operational tolerance.
Treg cells can be isolated and expanded in large scale from
the peripheral blood and the umbilical cord blood, which have
been infused back to patients and proved to be safe in graft vs.
host disease (GvHD) clinical trials (64, 65). Additionally, Treg
cells have been applied in renal transplantation clinical trials. In
the context of bone marrow transplantation, adoptive Treg cell
therapy has been applied to control GVHD by utilizing freshly
isolated or ex vivo expanded CD4+CD25+ Treg cells (65–67).
The TRACT trial infused 500–5000 × 106 CD4+ CD25+
Treg cells (>80% Foxp3+) to nine patients, 2 months after
live donor renal transplantation (68). The immunosuppression
regimens included Alemtuzumab, followed by mycophenolate
mofetil (MMF) and Tacrolimus. During this trial, there were
no reported cases of opportunistic infections or graft rejection.
In addition, the UCSF team applied polyclonal Treg cells
into renal allograft subclinical inflammation. This type of low-
grade inflammation can lead to late graft rejection, thus it
demonstrated the application of Treg cells in this context
(69). The team recruited three patients with biopsy-proven
inflammation and administered a dose of 320 million CD4+
CD25+ CD127low Treg (>93% Foxp3+) cells. Patients were
on MMF, tacrolimus, and prednisolone immunosuppression.
Following infusion, deuterated glucose was applied into the
culture media to track infused Treg cells in the circulation. There
were no side effects noted after infusion, however deuterated cells
were not detected at the site of renal inflammation.
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FIGURE 2 | Regulatory T cells in live and cadaveric liver transplant. Liver transplantation can be a living-related (right lobe graft- upper figure) or a cadaveric transplant
(whole liver transplant—lower figure). Renal transplantation can also be cadaveric or a live donor allograft. If it is a living donor transplantation, antigen-specific Treg
cells can be generated and expanded before transplantation whereby recipient Treg cells are co-cultured with donor dendritic cells, which are primed with donor
antigens (yellow dots). Both polyclonal and antigen-specific Treg cells proliferate and function via utilizing interleukin-2 as Treg highly express IL-2 receptor, CD25.
These generated Treg cells are applied in both autoimmune disease and transplantation clinical trials.
More recently, the application of Treg cells in renal
transplantation was studied in the ONE study (in press, Vol
395 May 23, 2020, Lancet). The ONE Study consisted of
seven investigator-led, single-arm trials done internationally at
eight hospitals in France, Germany, Italy, the UK, and the
USA (60 week follow-up). Included patients were living-donor
kidney transplant recipients aged 18 years and older. The
reference group trial (RGT) was a standard-of-care group given
basiliximab, tapered steroids, MMF, and tacrolimus. The trial has
just been completed and investigators concluded that regulatory
cell therapy is achievable and safe in living-donor kidney
transplant recipients, and is associated with fewer infectious
complications, but similar rejection rates in the first year.
Therefore, immune cell therapy is a potentially useful therapeutic
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FIGURE 3 | Microenvironmental factors in different organs. Local tissue microenvironmental factors in organ (heart, liver, kidney, bone marrow, islet cells)
transplantation. Infused Treg cells arrive to local tissue where they crosstalk with innate immune cells (macrophage, dendritic cells, monocyte, natural killer cells,
neutrophils) and adaptive immune cells (NKT, Mucosa associated invariant T cells, Treg, Th1, Th17 cells) in the local tissue. Treg cells localize in tissue with
pro-inflammatory cytokines (interleukin 1, 6 and 12, tumor necrosis factor (TNF) and interferon (IFN)), chemokines (CXCL and CCL) and local metabolites
(carbohydrate, fatty acid, peptides and vitamins). Infused Treg cell plasticity and their function in the local tissue microenvironment is dependent on these factors.
approach in recipients of kidney transplant to minimize the
burden of general immunosuppression.
POLYCLONAL REGULATORY T CELLS
AND LOW DOSE IL-2 THERAPY IN LIVER
TRANSPLANTATION
Liver transplantation has now become a standard therapeutic
option for patients with acute liver failure or end-stage
chronic liver disease. The ideal situation would be to achieve
operational tolerance, which is defined as successful withdrawal
of immunosuppression and to maintain a stable, preserved
graft function following transplantation (31, 70). However, less
than 20% of liver transplant recipients will achieve operational
tolerance (71). The majority of patients will require life-long
immunosuppression in order to control recipient immune
responses toward allogeneic major histocompatibility complex
(MHC) antigens from the donor liver graft and to reduce the risk
of graft rejection and graft loss (72). Whilst immunosuppression



































Lead institution Expansion: donor-specific or
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Active, not recruited yet
Type 1 diabetes
mellitus
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TABLE 2 | Immunosuppressive medications applied in autoimmunity and transplantation with their mechanisms, and impact on immune systems.




Broad suppression of pro-inflammatory
cytokines (74, 75)
Bind their cytosolic glucocorticoid




Mycophenolate mofetil (MMF) Purine is required for proliferation of T cells
and B cells
Block enzyme IMPDH resulting in inhibition
of de novo purine synthesis (76)
Down-regulate co-stimulatory molecules






IL-2 is crucial cytokines for Treg and T
effectors survival and function (25)
Inhibit intracellular phosphatase calcineurin




JAK3 signaling is critical to normal
homeostasis and function of T cells, B
cells, and NK cells; SCID in JAK3
mutations
JAK3 transduces signals downstream of




Sirolimus (more effective for
mTORC1), Everolimus
T cells differentiation (84, 85)
Selective Treg expansion compared to T
conventional cell in cell culture (86)
Inhibit downstream of PI3K and Akt via
mTORC1 and mTORC2





Promote activation of innate and adaptive
immunity




IL-6 leads to conventional T cells resistant
to Treg suppression, Destabilizes Treg by
inhibiting Foxp3 expression (88)
Pro-inflammatory cytokine promotes B




Both Treg and T effector cells express
CXCR3 (58, 89)
Migrate to inflamed tissue where




Suppress immune response by targeting
recently activated effector T cells that
express CD25
Block the IL-2-binding site of CD25 (90) Organ transplants





Inosine monophosphate dehydrogenase (IMPDH), phosphatidylinositol 3-kinase (PI3K), Akt. mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), Janus associated kinase
3 (JAK3).
has drastically improved survival rates over the last five decades,
there are detrimental side effects that impose substantial risks to
transplant recipients, such as: opportunistic infections, increased
susceptibility to sepsis, renal dysfunction, and an increased risk
of de novo malignancy (73). Immunosuppressive medications
generally used are steroids, MMF, Tacrolimus, and Sirolimus.
These medications have different impacts on different immune
cell subset, which has been described in detail, in Table 2.
If transplant tolerance is to be achieved, it is essential
that early inflammatory responses to allograft tissue must be
regulated (94). In comparison to other organ transplantations,
the liver is uniquely tolerant, which was first evidenced
in 1969 by Sir Roy Calne, who demonstrated that liver
allografts were accepted across MHC mismatch in pigs
without immunosuppression (95). CD4+CD25+Foxp3+ Treg
cells function by maintaining immunological self-tolerance of
the allograft, immune homeostasis, and suppression of immune
responses in order to reduce the destruction of tissue and
support the allograft (96). Within a transplanted liver and
hepatic draining lymph nodes, there is highly complex immune
cells interplay between effector T cells, Treg cells, and antigen
presenting dendritic cells (69). Dysregulation of effector T cell
response to transplanted antigens and failure of Treg cells
to suppress donor antigen-specific T effector cells leads to
transplant rejection.
Todo and colleagues first described the application of Treg
cells in liver transplantation. They infused autologous Treg-
enriched cell populations (Treg cell frequency range from 2.6–
16.9% of cell population) to ten living donor liver transplant
recipients 2 weeks following transplantation. Treg cells from
recipient lymphocytes are amplified by co-culture with irradiated
donor cells in the presence of anti-CD80/CD86 monoclonal
antibodies in vitro for 2 weeks. Additionally, liver recipients
underwent splenectomy. Liver transplant patients receivedMMF,
cyclosporine and tacrolimus during the post-transplant period.
The study showed that seven out of ten patients were successfully
withdrawn from immunosuppression, ranging from 6 to 18
months post-transplantation (97).
Furthermore, in a recent phase I clinical trial using
CD4+CD25+Foxp3+ GMP-Treg cells, it was revealed that
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Treg cell administration was safe in liver transplantation.
Peripheral blood Treg cells were isolated by leukapheresis and
expanded under GMP conditions with IL-2 and rapamycin and
subsequently administered to post-liver transplant patients at
either 0.5–1 million/Kg or 3–4.5 million/kg. A total of nine
patients (three patients less than 6 months after transplantation
and six patients more than 6 months post-transplantation)
received the GMP-Treg cells. The study showed that Treg cell
therapy was safe and increased the pool of circulating Treg
cells (98).
In addition to GMP-Treg cellular therapy, IL-2 has also
been applied in liver transplant recipients to enhance Treg
cell frequency and function. Treg cells constitutively express
the high affinity IL-2 receptor, which makes them exquisitely
sensitive to very low-doses of IL-2. A clinical trial to test
the capacity of low-dose IL-2 in order to promote the
selective expansion of endogenous Treg cells in liver transplant
recipients is still on-going and results are awaited (LITE
trial, NCT02949492).
IMMUNOSUPPRESSIVE MEDICATIONS
AND REGULATORY T CELLS
Either single or combination of immunosuppressive
medications is normally applied in both AIDs and following
organ transplantations. Calcineurin inhibitors (Tacrolimus
and cyclosporine), mycophenolate mofetil (MMF or
myfortif), Sirolimus, and corticosteroids are commonly
used immunosuppressive drugs in both contexts. Rituximab, B
cells depleting therapy, is also widely used in SLE and recently
in difficult-to-treat AIH. Anti-cytokine therapy (anti-TNF and
anti-IL-6) and JAK inhibitors have been applied in AIDs. Table 2
describes the types of immunosuppressive medications, their
impact on immune cells and their mechanisms of action (99).
DEVELOPMENT OVER LAST DECADE
Target Tissue Homing and Tracking of
Tregs
In order for Treg cells to exert their suppressive ability to tissue
damaging effector T cells, cellular migration to the target tissue
is essential. A recent study by our laboratory demonstrated that
22–44% of indium labeled GMP clinical grade Treg cells could be
detected in the inflamed human liver by SPECT CT scan (60).
These GMP Treg cells had high levels of CXCR3 expression.
CXCR3 ligands (CXCL9, CXCL10, CXCL11) are expressed on
the sinusoids, hepatocytes, and bile ducts in the inflamed liver
(60, 100). Thus, up-regulating chemokine receptors on the Treg
cells or enhancing chemokine expression at the target tissue
site would be an option to achieve homing of Treg cells in
both organ specific AID and transplantation. Labeling of GMP
Treg cells with deuterium can track the infused cells in the
peripheral circulation (38) and hence can be applied to track
cells for longitudinal phenotyping. Labeling of GMP Treg cells
with indium and tracking the cells in real time with SPECT-
CT scan would be an alternative way to reassure that cells that
express tissue specific chemokine receptors migrate to the target
tissue (60).
Current Treg cell manufacturing technologies are only
available for large-scale polyclonal Treg cell production.
Polyclonal Treg cells can be expanded using anti-CD3 and
anti-CD28-coated beads and subsequent supplementation with
IL-2 (101). The use of large numbers of polyclonal Treg cells
with unknown antigen specificities has led to unwanted effects,
such as systemic immunosuppression, which can be avoided via
utilization of antigen-specific Treg cells.
Antigen Specificity and Chimeric Antigenic
Receptor Tregs
Antigen-specific chimeric antigen receptor (CAR)-Treg cells
have an advantage compared to polyclonal Treg cells due to
their ability to migrate to the target organ, which express a
specific antigen. Antigen-specific Treg cells have been shown
to be functionally superior to polyclonal Treg cells in animal
models, for example, Tang and colleagues isolated and expanded
Treg cells derived from a transgenic mice that expressed islet
cell specific TCR (102). In addition, antigen-specific CAR-
Treg cells migrate specifically to the site of the antigen,
thus has the advantage of less global immunosuppression
compared to polyclonal Treg cells. CAR Treg cells could be
developed to redirect Tregs toward a specific donor leucocyte
antigen (HLA) class I molecule (HLA-A2) that is expressed
in grafts.
Autologous or allogenic choice of Treg cell will influence
the timing of administration for cell therapy. Donor-derived
or third-party cells, such as umbilical cord blood derived
Treg cells, may be used to generate CAR-Treg cells rapidly
in batch production, however they could be immunogenic.
Yet, autologous CAR-Treg cells, although not immunogenic,
are produced individually, which is time-consuming (31).
Other major challenges of Treg cell immunotherapy is the
manufacturing of a large number of Treg cells to provide timely
delivery of therapy, the efficacious dose of cells, the frequency of
administration and recently, a major question being, what role
does the low dose of IL-2 play in enhancing survival and function
of polyclonal and antigen-specific Treg cells (28).
There are different approaches to obtain antigen-specific Treg
cells and these include conferring antigen expression via CARs
or engineering Treg cells with TCRs, specificity via transfection
of viral vectors encoding specific TCRs. Both types of cells
are promising given that they preferentially migrate to target
sites and exert more potent and specific immunosuppression
than polyclonal Treg cells. Engineering Treg cells with TCRs
is a promising approach but limitations occur due to MHC-
restrictions. Alloantigen-reactive Treg cells can be expanded
through donor APCs, such as dendritic cells, PBMCs, and B
cells (103). Compared to Treg cells engineered with TCRs (TCR-
Treg), CAR-modified Treg (CAR-Treg) cells engineered in a
non-MHC restricted manner have the advantage of widespread
application. Additionally, CAR-Treg cells are less dependent on
IL-2 than TCR-Treg cells.
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Large Scale Treg Cell Production
Many investigators now have a GMP cell production facility and
apply large scale Treg cell isolation and expansion. Cells are
then frozen in GMP condition and thaw before infusing back to
patients (Figure 4).
The quality of Treg cell function can be assessed before
infusion by phenotyping isolated Treg cells to make
sure that the purity is more than 95% (CD4+ CD25high
and CD127low), with a high level of transcription factor
Foxp3 expression. Flow cytometry analysis can also be
applied to assess functional markers of Treg (CD39, CTLA-
4, IL-10) on the isolated and expanded Treg cells. In
addition, quality of Treg cells can be assessed by epigenetic
testing of isolated and expanded GMP Treg cells with
analysis of Treg specific demethylated region (TSDR) with
epigenetic analysis.
Treg therapeutic effect could be predicted by clinical readouts.
For example, in the context of liver disease to assess whether Treg
cell infusion could improve liver function tests (liver enzymes—
alanine transaminase and aspartate transaminase, bilirubin)
and in the context of diabetes (insulin requirement and c-
peptide level improvement). Also, Treg therapeutic effect can be
monitored with immunological readouts (e.g., decline in effector
Th1 or CD8+ T cell frequency in the blood and assessing the
FIGURE 4 | Schematic illustration of large scale GMP Treg production. Leukapharesis procedures are performed to those patients with either autoimmune diseases or
those who will undergo transplantations. GMP Treg will be cell sorted using surface markers to obtain highly pure CD4+ CD25high CD127low cells population. Then,
cells will be expanded in GMP culture media with GMP-grade IL-2 cytokines, GMP-grade rapamycin (to prevent effector T cells outgrowth) and GMP-grade CD3,
CD28 Treg expander beads (with or without known antigen). These cells will then undergo quality assessment process and will be frozen until infusion back to patients.
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frequency of cells in the tissue before and after infusion of cells
with liver biopsy).
It is crucial to monitor the persistence of Treg cells when
deciding the timing and frequency of Treg cells infusion. Treg
cells can be monitored in both peripheral circulation and at tissue
level. A recent study by our group showed Indium tropolonate
labeling (60) and Deuterium labeling (38) can be applied to
investigate the persistence of Treg cells in the circulation.
Furthermore, persistence of infused Treg cells can sometimes be
assessed in the tissue by performing a biopsy if it is ethically
feasible and approved by the local team.
Treg cell function after infusion can be assessed directly by
tracing the infused GMP Treg cells and conducting suppressive
assays with autologous effector T cells, or indirectly by
longitudinal phenotyping of effector T cells to investigate the
decline in the frequency of these cells.
REGULATORY T CELLS IN CLINICAL
TRIALS IN LIVER TRANSPLANTATION AND
AUTOIMMUNE DISEASES
Current Treg cell therapy use autologous cells. The drawback of
using autologous cells is the time-delay to administer Treg cells
from taking peripheral blood to obtaining sufficient numbers
of cells. To achieve the Treg cell infusion at the time of
transplantation, allogeneic Treg cells produced by umbilical
cord blood would be a potential option. In addition, live
donor transplantations (liver and kidney) would also allow the
investigator to obtain sufficient numbers of functional Treg cells
before the day of organ transplantation. It is crucial to obtain
tissue biopsies following Treg infusion to access the localization
of infused cells. A recent study focusing on skin biopsies of
lupus lesions following Treg cell infusion suggested that there
was a shift in Th1 to Th17 gene signature (44). In addition, the
choice of immunosuppression in patients with Treg cell therapy
is crucial, for example, rapamycin has been shown to enhance
Treg cell frequency (104). To achieve efficacious and successful
Treg therapy, it is necessary to continue on immunosuppression
that is favorable to Treg cell survival and proliferation.
Application of CAR-Treg cells is an exciting option, in both
transplantation and AID, where there is a known antigen.
However, there are still major hurdles that must be overcome
before CAR-Treg cells can be used in clinic. Antibodies specific
for self- or alloantigen must be characterized to construct
antigen-specific CAR-Treg cells. Additionally, it is crucial to
achieve homing of CAR-Treg cells to the exact target site.
Treatments with anti-tumor CAR-T cells cause side effects
such as a cytokine “storm” and neuronal cytotoxicity (105).
Yet, exhaustion of CAR Treg cells may limit their efficacy
in immunosuppression. Therefore, more work is required to
administer CAR-Treg cells effectively and safely to restore
tolerance in transplantations and AIDs.
Plasticity of polyclonal or CAR-Treg cells in an inflamed
microenvironment is still an unknown factor and concern to
most investigators. Some data suggested that the plasticity and
instability of cells in inflamed tissue and Treg cells could
convert into pathogenic effector T cells (106, 107). The inflamed
microenvironment enriched with pro-inflammatory cytokines
can either lead to a reduction in the potency of Treg cells
or resistance of T effector cells to Treg cell suppression
(25). There are also questions to be addressed regarding the
long-term proliferative potential and survival of polyclonal
or antigen-specific Treg cells in the tissue microenvironment,
which is enriched with cytokines, metabolites, low oxygen
levels, and microbial peptides (in the context of liver) (107,
108). Additionally, metabolites and microbes from the portal
vein toward the liver can have an impact on metabolism,
phenotype, and function of intrahepatic Treg cells. These
microenvironmental factors will determine the biology of GMP
Treg cells at the specific tissue locations. Treg cells co-localize
not only with effector CD4+ and CD8+ T cells but also with
other immune cells, including antigen presenting dendritic cells,
microbes-primed MAIT cells, phagocytic macrophages, innate
NK cells, and neutrophils (109). The cross talk of Treg cells
with other immune cells and microenvironmental factors will
shape the phenotype and function of Treg cells; thus it is worth
considering these factors for each tissue when designing Treg cell
clinical trials (Figure 3).
EXTRACELLULAR VESICLES
Recently, it has been reported that intracellular communication
of Treg cells can occur through extracellular vesicles (EVs),
which include exosomes, apoptotic vesicles, and macrovesicles
(110) Importantly, they appear to be involved in alloimmunity,
thus, EVs may be an alternative therapeutic approach. EVs
were identified in CD4+CD25+ Treg cells isolated from rodents,
which were found to be produced after TCR activation. Smyth
and colleagues identified that CD73 was present on Treg-derived
EVs, which was essential for Treg cell mediated suppression. To
support this, Yu and colleagues reported that in an in vitro kidney
transplantation mouse model, Treg-derived EVs effectively
suppressed T cell proliferation in a dose-dependent manner
(111). Patients with relapsing-remitting multiple sclerosis had
Treg-derived exosomes with impaired suppressive function (112,
113). It has been previously shown that in an autoimmune
colitis model, Treg exosomes suppressed inflammatory T cell
immunity, thereby preventing systemic inflammation, through
transfer of IFN-y suppressing miRNA to T helper cells (114).
Tung and colleagues identified that human Treg-derived EVs
may be immune regulators and could be a potential treatment
of transplant rejection (115). They also reported that TCR-
activation of human Treg cells resulted in a release of EVs
that efficiently suppressed T cell proliferation. Additionally, they
identified that EVs had the ability to alter their cytokine profile
to favor IL-10 and IL-4 secretion, whilst reducing expression
of IL-6, IL-2, and IFN-y simultaneously (116). In line with
this evidence, the group demonstrated that in a humanized
mouse skin transplant model, human Treg-derived EVs were
capable of protecting human skin grafts from alloimmune-
mediated damage, through reducing immune cell infiltrate, thus
supporting that EVs may be immune regulators, and thus an
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important therapeutic alternative. It is noteworthy that EVs
derived from dendritic cells have previously been utilized in
phase 2 clinical trials for non-small cell lung cancer therapy and
were identified to be efficacious (116). This suggests that EVs
may be a promising therapeutic option, however there are many
limitations that would be necessary to address prior to EVs being
utilized in a clinical setting, including, but not limiting to, the
dose regimen, optimization of ex vivo isolation of GMP-grade
Treg-derived EV protocols, and identification of in vivo targets.
FUTURE DIRECTION OF REGULATORY T
CELLS IN TRANSPLANTATION AND
AUTOIMMUNITY
Treg cells have proved to be a major breakthrough as an
exciting immunotherapy option in the last two decades.
Early phase clinical trials demonstrated safety, feasibility, and
early efficacy with GMP Tregs therapy in both autoimmune
diseases and organ transplantation. Achieving successful Treg
immunotherapy would lead to an immunosuppression-free
period for patients. Development of antigen-specific Treg cells
and CAR-Treg cells would lead to exciting new frontiers in the
cell therapy field as these cells are more efficacious and lesser
numbers of cells will be required due to their target tissue homing
affinity. Over the last decade, manufacturing processes and
culture media has been optimized. In addition, cytokines, such
as IL-2, can support infused Treg cell survival and they would
play as an adjuvant therapy in GMP Treg trials. Additionally,
enhanced understanding of the patient’s OMICs profile with
new technologies will also allow us to apply personalized
Treg cell immunotherapy. Although there are challenges, the
future is exciting for the cell therapy community to collaborate
closely in order to achieve a potentially effective immunotherapy
and replace immunosuppression in both autoimmune disease
and transplantation.
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